Skin diseases such as atopic dermatitis and alopecia areata can have a substantial negative impact on a patient by affecting their quality of life (QoL), resulting in a burden to the patients at a physical, psychosocial, and mental level. Awareness and understanding of these diseases have been increasing globally with the introduction of innovative treatments that can address some of the historic unmet needs in this space. However, discussions around these diseases at a healthcare policy level is limited in Latin America. This is primarily driven by a lack of information around the impact of the diseases in a local context, society’s perception of the diseases as being “cosmetic”, type of physical manifestations that are not considered as disabilities, and lack of optimal coverage of innovative treatments.